Revisiting maintenance therapy in acute myeloid leukemia with novel agents

Jonathan Canaani, Selina M. Luger*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Purpose of review High relapse rates and therapy-related toxicity contribute to suboptimal outcomes in acute myeloid leukemia (AML) patients attaining a remission following initial induction therapy and postallogeneic stem cell transplant. Maintenance therapy holds the potential for a prolonged remission interval analogue to that seen in other hematologic malignancies. Herein we present and analyze the current data in the field. Recent findings Maintenance treatment approaches utilizing conventional chemotherapy, immunomodulation, hypomethylating agents, targeted small molecules, and tyrosine kinase inhibitors have been explored in this setting. The published data have not yet demonstrated convincing efficacy to merit establishment of this approach as standard of care. The role of hypomethylating agents and novel tyrosine kinase inhibitors is being actively studied in phase II/III trials and may improve patient outcome. Summary Maintenance therapy has not been shown to improve patient outcome in AML. The results of ongoing and future studies with novel agents may facilitate incorporation of this approach to standard care of AML.

Original languageEnglish
Pages (from-to)175-180
Number of pages6
JournalCurrent Opinion in Hematology
Issue number2
StatePublished - 1 Mar 2016
Externally publishedYes


  • acute myeloid leukemia
  • allogeneic bone marrow transplant
  • maintenance therapy
  • tyrosine kinase inhibitors


Dive into the research topics of 'Revisiting maintenance therapy in acute myeloid leukemia with novel agents'. Together they form a unique fingerprint.

Cite this